The purpose of this paper is to explore variables to be considered in developing a successful, well-managed EAP that provides access to investigational treatments to patients with terminal or severely debilitating disease and for whom commercially available treatment have failed. The EAP will provide access in a manner that:
1. Does not threaten enrollment in or conduct of controlled clinical trials for the drug
2. Meets all regulatory requirements
3. Does not pose added risk to patient safety and
4. Can be financially sustained
EAPs are not set up to support commercial objectives nor are they meant to support analysis or test a hypothesis, though sometimes the data have been very useful in a supplementary fashion.